Webdisclosure.com

Search

MEDACTA GROUP SA Medacta Receives CE Marking for the Lateralized Glenosphere

Directive transparence : information réglementée

08/10/2019 19:05


EQS Group-Media / 08.10.2019 / 19:05

Press Release
Medacta Receives CE Marking for the Lateralized Glenosphere

CASTEL SAN PIETRO, 8 October 2019 - Medacta International has recently obtained CE marking for the lateralized glenosphere. This new implant further expands the Medacta offering for shoulder arthroplasty, which now features a broader range of options for reverse shoulder replacement surgery.

The Medacta Shoulder System is a modular solution that includes wide-ranging sizes, adjustable offset and innovative configurations both in the anatomic and reverse configuration. It is compatible with, and can be further enhanced by, the CT-based MyShoulder 3D preoperative planning solution, offering patient-specific humeral and glenoid guides.

The lateralized glenosphere features a more lateralized centre of rotation compared to the standard glenosphere already included in the Medacta Shoulder System offering. The potential benefits are an improved range of motion, as well as a reduced risk of scapular notching.

This new CE mark clearance exemplifies Medacta's continuous commitment to leverage expertise gained throughout orthopaedics for the development of exceptional shoulder solutions.

For more information on Medacta Shoulder System and Medacta's shoulder arthroplasty solutions, visit https://www.medacta.com/EN/global-shoulder.

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specializing in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated "MySolutions" technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=LRTMPBMUWY
Document title: Medacta Receives CE Marking for the Lateralized Glenosphere


Issuer: Medacta Group SA
Key word(s): Advertisement/Communication

End of Corporate News


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 887253

 
End of News EQS Group Media

887253  08.10.2019 

fncls.ssp?fn=show_t_gif&application_id=887253&application_name=news&site_id=symex